Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Section 7.01 disclosure contains only a securities-law liability disclaimer.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Section 7.01 disclosure contains only a securities-law liability disclaimer
- No operating, financial, clinical, or strategic information for investors
- No actionable market update disclosed in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- FDA advisory committee presentation supports accelerated approval for TUDRIQEV plus nivolumab in anti-PD-1–failed advanced melanoma
- IGNYTE showed 33.6% ORR, including 16.4% complete responses, with median response duration of 24.8 months
- Three-year overall survival reached 47.8%, while three-year ongoing-response rate was 44.8%
- Safety was primarily Grade 1–2; 31.4% experienced Grade 3+ adverse events and no treatment-related Grade 5 events were reported
- Key regulatory risk: randomized IGNYTE-3 confirmatory OS data are not expected until 2030, extending approval uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.